RV Group has 5 advanced pharmaceutical formulation manufacturing facilities located in India, Vietnam and Kazakhsthan. These facilities are approved by stringent regulatory authorities such as EU, PIC/S, Russia, WHO, Tanzania, Uzbekistan and other regulatory organisations.

To achieve our targets, we have applied and integrated international standards in our quality systems, documentation, and processes to ensure current Good Manufacturing Practices (cGMP) compliance. At these facilities, we manufacture wide range of products on a large-scale in dosage forms such as tablets, film-coated tablets, capsules, ointments, Large Volume Parenterals, Small Volume Parenterals, Betalactam oral and Injection, Oral powder, Disinfectants etc..

With well-experienced pharmacists and professionals back by comprehensive training, we are confident that our quality is a trusted choice for consumers and contract manufacturing by multinational pharma companies worldwide.

RVLL (formerly Atra Pharmaceuticals  manufacturing unit, located in Aurangabad, Maharashtra, India, is accredited by EU (Infarmed Portugal), PIC/S (Malaysia), WHO GMP, Russian GMP, Uzbekistan and Tanzania. RVLL also has ISO 9001:2015, 14001-2015 and 45001-2018 accreditation giving us comprehensive assurance on our processes, sytems, logistics, Health and Safety practices as well as Environment and energy efficiency.  We are focused on providing high quality products for our multinational partners in the EU and Asian Regions.

The pharmaceutical unit can produce up to 2 billion units in general purpose oral dosage forms such as tablets, film-coated tablets and capsules .

RV Lifesciences also has a dedicated research and development (R&D) centre for a range of antiviral, anti-hypertensive, anti-diabetics, lipid lowering agents, analgesic, antipyretic drugs, etc. This world-class R&D centre is built for product development and launching products across the world and is also the hub for technology transfer to our facilities across the Globe.

The facility is located in the rural district of Cu Chi, few kilometres from Ho Chi Minh city. BRV’s manufacturing facility is accredited with WHO GMP and has the capability to produce high quality medicinal products.

BRV is also the first company to have dedicated oncology facility and number of registered products like Imatinib, Erlotinib and Gefitinib as well as being the national tender winner for oncology products. It is also the first Vietnamese company to get registration for Hep C products such as fixed dose combination of  Sofosbuvir  and Ledipasvir, Sofosbuvir and Daclatasvir.

BRV is a reputed pharma company with well-established market presence having more than 247 active product licenses and brands in both OTC and ETC segments as well as having a strong herbal product portfolio. BRV has a long history with well-trained manpower. The company has good manufacturing capabilities with general solid line including tablets, capsules, syrups, sachets, effervescent tablets, creams, oncology OSD, SVP and herbal line.

Cumulatively BRV has a very healthy product grid with more than 105 product registrations and 48 unique products under development. Recently BRV has formed under licensing and tech transfer cooperation with Natco and Himalaya (Herbal). BRV has also secured under licensing agreement for insulin repackaging from a European manufacturer.

The success story of RV OPV Pharmaceutical began some 65 years ago in Vietnam. RV OPV brands are very well known and established in Vietnam market. They also are known to develop pharma products for third party distributors and provide manufacturing contract services to Multinational Pharma companies in the region. RV OPV factory is WHO-GMP certified and adheres to highest international quality standards.

RV OPV has the largest portfolio of registered pharmaceutical products in Vietnam, including OTC and prescription formulations across all important therapeutic classes.

In 2021 RV OPV was merged with RV group to further the growth story of the pharmaceutical industry in Vietnam. And Our vision is to be the finest provider of world class quality healthcare products at affordable prices. This vision is supported by our core values that are focused, fast, flexible and forward looking.

Our vision is to strengthen biosimilars and high-end oncology product portfolio; expand and upgrade world class manufacturing units and R& D centers; to build the OTC segment in to mega brands like Ameflu, Star, Dizzo, Lomac, Flucort, NeuGlow and to maintain the leadership in the region for Hepatitis and Biosimilar product range. All these are directed toward one goal- our vision to be the finest provider of world class quality healthcare products at affordable prices.

RV OPV is also set to undergo EU inspection in 2023 to further buttress its position as premier player in the market.